Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterising the Gut Microbial Ecosystem for Diagnosis and Therapy in IBD

ABSTRACT: Characterising the Gut Microbial Ecosystem for Diagnosis and Therapy in IBD

PROVIDER: PRJNA476195 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Characterising the Gut Microbial Ecosystem for Diagnosis and Therapy in IBD

Project description:Characterising the Gut Microbial Ecosystem for Diagnosis and Therapy in IBD

| PRJNA476196 | ENA

16S RNA gene sequencing for IBD therapy

Project description:16S RNA gene sequencing for IBD therapy

| PRJNA917250 | ENA

Whole blood expression profiling of patients with inflammatory bowel diseases in IBD-Character cohort

Project description:The IBD-Character cohort (Edinburgh, Oslo, Örebro, Linköping, Zaragoza, Maastricht) included patients with inflammatory bowel diseases (IBD: Crohn's disease, ulcerative colitis) recruited at diagnosis and non-IBD controls. Paired-end RNA sequencing was used for whole blood expression profiling. Raw and normalized counts tables are provided.

2022-03-01 | E-MTAB-11349 | biostudies-arrayexpress

RNAseq of pedriatic IBD and XIAP-deficient biopsy samples

Project description:Deficiency in the X-linked inhibitor of apoptosis protein (XIAP) is the cause for the X-linked lymphoproliferative syndrome 2 (XLP2). About one third of all patients suffers from severe and therapy refractory inflammatory bowel disease (IBD), but the exact pathogenesis remains undefined. We examined the differences in gene expression of pediatric XLP2 patients with IBD to healthy controls and pediatric IBD patients.

2021-09-20 | GSE183069 | GEO

Predicting response to vedolizumab therapy using mucosal transcriptomics in IBD patients

Project description:Predicting response to vedolizumab therapy using mucosal transcriptomics in IBD patients

| PRJEB32016 | ENA

Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy

Project description:Purpose: IBD diagnosis correlation with failure to achieve corticosteroid-free durable remission upon anti-TNF therapy Results: Enrichment of the GIMATS module (unique cellular signature found in a small cohort of surgically resected iCD ileums by scRNAseq) was also present in early stages of disease, prior to any biological therapy Conclusion: Confirmed the presence of the GIMATS module in bulk expression dataset and revealed that the presence of the module at diagnosis is associated with failure to achieve durable corticosteroid-free remission upon anti-TNF therapy in a pediatric inception cohort

2019-08-21 | GSE134881 | GEO

Low mass blood peptides discriminative of IBD severity

Project description:The enriched low mass proteome is unexplored as a source of differentiators for diagnosing and monitoring Inflammatory Bowel Disease (IBD) activity, less invasively than colonoscopy and histopathology. Differences in the enriched low mass plasma proteome (<25kDa) were assessed by label-free quantitative mass-spectrometry. A panel of marker candidates were progressed to validation phase and ‘Tier-2’ FDA-level validated quantitative assay. Proteins important in maintaining gut barrier function and homeostasis at the epithelial interface have been quantitated by Multiple Reaction Monitoring (MRM) in plasma and serum including both inflammatory rheumatoid arthritis controls (RA) and non-inflammatory healthy controls (C), ulcerative colitis (UC) and crohn’s disease (CD) patients. Detection by immunoblot confirmed presence at the protein level in serum. Correlation analysis and receiver operator characteristics were used to report the sensitivity and specificity. Five peptides discriminating IBD activity and severity had very little-to-no correlation to Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white cell or platelet counts. Three of these peptides were found to be binding partners to SPP24 protein alongside other known matrix proteins. These Proteins have the potentially improve effective diagnosis and evaluate IBD activity, reducing the need for more invasive techniques.

2015-11-06 | PXD002821 | Pride

Pediatric IBD MLI metaproteomics

Project description:Mucosal-luminal interface (MLI) samples were collected from a cohort of children with new-onset IBD and microbial cells were harvested and processed for metaproteomic analysis. Deep metaproteomics data analysis was then performed for better understanding the MLI microbiota functions in the development of pediatric IBD.

2018-08-03 | PXD007819 | Pride

IGNITE: Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes

Project description:IGNITE: Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes

| PRJNA515545 | ENA

IGNITE: Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes

Project description:IGNITE: Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes

| PRJNA515546 | ENA